Keyphrases
High Performance Liquid Chromatography-tandem Mass Spectrometry (HPLC-MS/MS)
58%
Analytical Method
42%
Liposomal Amphotericin B
42%
Dried Blood Spots
41%
Clinical Validation
29%
MS Method
29%
Everolimus
28%
Human Plasma
28%
Osimertinib
28%
Pharmacokinetics
26%
Small Molecule Inhibitors
25%
EDTA Plasma
24%
Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS)
22%
Room Temperature
21%
Pharmacokinetic Study
20%
Plasma Concentration
18%
Pralsetinib
17%
K2EDTA
17%
Selpercatinib
17%
Lorlatinib
17%
Brigatinib
17%
Validation Studies
15%
Methanol
14%
Multiplexing
14%
Stability Results
14%
Gefitinib
14%
Adagrasib
14%
Sotorasib
14%
Patients with Cancer
14%
Acquired Resistance
14%
UHPLC-DAD
14%
Colorectal Cancer
14%
Dried Blood Spot Samples
14%
Mycophenolic Acid
14%
Human Plasma Samples
14%
Critically Ill Patients
14%
Ultra-performance Liquid Chromatography
14%
Erlotinib
14%
Tacrolimus
14%
Morbid Obesity
14%
Crizotinib
14%
Alectinib
14%
Resistance to Targeted Therapy
14%
BRAF mutant
14%
Molecular Landscape
14%
Oncology Setting
14%
Nitrofurantoin
14%
Fixed Dosing
14%
Amphotericin B
14%
Drug-drug Interaction Study
14%
Analytical Validation
14%
Raltegravir
14%
Citalopram
14%
Pharmacokinetic Drug Interactions
14%
Obese Men
14%
Combination of Therapies
14%
Chromatographic Separation
12%
Mass Spectrometry Methods
11%
Resistant Cells
10%
BRAF Inhibitor (BRAFi)
10%
Ammonium Acetate
10%
UPLCâ„¢
10%
Non-small Cell Lung Cancer (NSCLC)
9%
Whole Blood
8%
Clinically Significant
8%
Protein Precipitation
8%
Formic Acid
8%
Mass Spectrometer
8%
C-18
8%
Prediction Error
8%
Sample Preparation
7%
Cancer Patients
7%
Photodiode Array
7%
Ultra-high Performance Liquid Chromatography (UHPLC)
7%
Clinical Trials
7%
Resistant Cell Lines
7%
Mutant BRAF
7%
Therapeutic Combinations
7%
Within-day
7%
Body Size
7%
Mitogen-activated Protein Kinase
7%
Clinical Trial Registry
7%
Fixed-dose Combination
7%
Quad
6%
KRAS G12C mutation
6%
Electrospray Ionization Interface
6%
Clinical Practice
5%
Therapeutic Drug Monitoring
5%
Toxicity Profile
5%
Passing-Bablok Regression
5%
INIS
validation
100%
plasma
95%
concentration
66%
patients
58%
humans
57%
blood
52%
cancer
48%
hplc
42%
drugs
42%
temperature range 0273-0400 k
35%
edta
31%
liquid column chromatography
29%
range
27%
doses
26%
accuracy
24%
methanol
23%
mass spectrometry
21%
precision
20%
high-performance liquid chromatography
20%
detection
19%
stability
19%
performance
18%
chromatography
18%
water
18%
sampling
17%
acetates
16%
therapy
15%
lung cells
15%
children
14%
molecules
14%
interactions
14%
mutants
14%
urine
14%
ionization
13%
mass spectrometers
13%
formic acid
13%
clinical trials
11%
sample preparation
11%
interfaces
10%
precipitation
10%
proteins
10%
lead method
10%
photodiodes
9%
auc
9%
mutations
9%
toxicity
9%
carbon 18
8%
carbon 20
7%
size
7%
hiv
7%
tyrosine
7%
clearance
7%
kinases
7%
acetonitrile
6%
monitoring
6%
prediction
5%
errors
5%
data
5%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
58%
Amphotericin B
42%
Ultra High Performance Liquid Chromatography
33%
Ethylenediaminetetraacetic Acid
32%
Everolimus
28%
Brigatinib
28%
Lorlatinib
28%
High Performance Liquid Chromatography
28%
Methanol
23%
Non Small Cell Lung Cancer
22%
Malignant Neoplasm
16%
Acetonitrile
15%
Gefitinib
14%
Ammonium Formate
14%
Erlotinib
14%
Tacrolimus
14%
Mycophenolic Acid
14%
Crizotinib
14%
Osimertinib
14%
Nitrofurantoin
14%
Alectinib
14%
Drug-Drug Interaction
14%
Raltegravir
14%
Citalopram
14%
Connective Tissue Cancer
14%
Electrospray Ionization
8%
Formate
8%
Ammonium Acetate
8%
Clinical Trial
7%
Prospective Study
7%
Therapeutic Drug Monitoring
5%